Akribion Therapeutics raises €8.0M Seed round

The company intends to use the seed capital to achieve in vivo proof of concept for its proprietary G-dase® E technology and to accelerate the development of novel therapeutics for precision disease cell depletion, initially targeting oncology.

Source: https://akribion-therapeutics.com/akribion-therapeutics-exits-from-stealth-with-e8m-seed-financing-to-pioneer-rna-guided-programmable-cell-depletion/